查詢結果分析
相關文獻
- 成功使用血栓溶解劑治療急性缺血性腦中風:一病例報告暨文獻回顧
- 使用血栓溶解劑治療急性缺血性腦中風--病例報告
- 急性缺血性腦中風靜脈注射血栓溶解劑治療
- 急性缺血性腦中風的藥物治療及預防趨勢
- 運用實證醫學改善急性缺血腦中風靜脈血栓溶劑施打成效
- 「急」刻救援--急性腦中風病人面臨施打rt-PA的急診護理經驗
- 改善急性腦中風病人血栓溶解治療評估效率之經驗及探討
- 急性缺血性腦中風治療的發展與展望
- Successful Delayed Thrombolytic Therapy in a Patient with Massive Pulmonary Embolism
- 以動脈注射血栓溶劑治療急性缺血性腦中風:七例報告
頁籤選單縮合
題 名 | 使用血栓溶解劑治療急性缺血性腦中風--病例報告=Usage of Intravenous Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke--A Case Report |
---|---|
作 者 | 高偉峰; 凌憬峰; 徐德福; 郭孝齡; 翁文章; 李建賢; | 書刊名 | 中華民國急診醫學會醫誌 |
卷 期 | 1:2 1999.08[民88.08] |
頁 次 | 頁174-180 |
分類號 | 415.922 |
關鍵詞 | 急性缺血性腦中風; 血栓溶解劑; Ischemic stroke; Acute; Plasminogen activator; Tissue-type; Thrombolytic therapy; |
語 文 | 中文(Chinese) |
中文摘要 | 對於急性缺血性腦中風病患,在臨床上使用血栓溶解劑治療之前,並沒有直接的治療可減低神經傷害的範圍。自從1995年,美國的一項大規模的研究報告證實血栓溶解劑rt-PA(recombinant tissue-Plasminogen Activator)可有效地改善急性缺血性腦中風病患的神經症狀及功能後,美國藥物食品管理局(FDA, Federal Drug Administration)於1996年六月,即通過使用靜脈注射rt-PA,來治療症狀發作三小時內沒有禁忌症的急性缺血性腦中風病患。 國內的腦中風病患的發病率向來較歐、美、日等國為高,隨著老年人口的增加,使得好發於老人之腦梗塞病例更有逐漸增加的趨勢。但目前國內上無使用rt-PA治療急性缺血性腦中風的病例報告。 在此謹報告一位68歲女性的急性缺血性腦中風病患,他在發病三小時內到達急診室且完成了腦部電腦斷層的檢查,在沒有禁忌症且經家屬同意的情況下,在急診室即給予靜脈注射rt-PA,大約在靜脈注射rt-PA二至三小時左右,意識及肢體力量有明顯的改善。希望藉以提醒大家對腦中風的新治療的重視。 |
英文摘要 | Prior to the clinical use of thrombolytic agents, there was no effective treatment that could directly reduce the neurological consequences for acute ischemic stroke. After a positive result from large series of trials, intravenous recombinant tissue plasminogen activator (rt-PA) was approved by FDA (Federal Drug Administration) to be used in acute ischemic stroke patients in 1996. This concept was also put into the new textbook of ACLS (Advanced Cardiac Life Support) as a chapter in 1997. Although, the concept concerning the use of rt-PA in acute ischemic stroke patients has been acknowledged by many doctors, it is still not yet being practiced widely in Taiwan. The incidence of stroke in Chinese is much higher than that of the people in the west. The usage of rt-PA in ischemic stroke patients was still not approved by National Central Health Insurance Bureau of Taiwan at present. There was no documented report regarding the use of intravenous rt-PA in ischemic stroke in Taiwan. We are going to report a case who developed ischemic stroke and had good outcome after using intravenous rt-PA within 3 hours from the onset of stroke. Although the incidence of intracerebral hemorrhage in Taiwan was reported higher than that in the western countries, based on our limited experience, early use of intravenous rt-PA should still be encouraged in acute ischemic stroke patients here in Taiwan. |
本系統中英文摘要資訊取自各篇刊載內容。